The Quiet Number in the Blood

The tube fills dark and ordinary. Nothing about the blood announces what the laboratory will look for: not the C-reactive protein of infection, which surges high enough for any standard assay to see, but the residue of a slower fire — concentrations resolved in fractions of a milligram per liter, the range where the high-sensitivity assay earns its name. When the result returns, it will sort the patient into one of three bands used in cardiovascular risk assessment: below 1 mg/L, lower relative risk; 1 to 3, average; above 3, higher.

The protein itself is made by the liver, an acute-phase respondent to inflammation anywhere in the body. The test's premise is that atherosclerosis is in part an inflammatory process — that the faint, persistent signal in the blood is a message from the artery wall. No one in the laboratory says any of this out loud. Unlike the standard CRP assay used to detect overt infection or autoimmune flares, this high-sensitivity version exists to resolve the small differences relevant to long-term risk stratification in otherwise healthy people. The instrument reads; the bands assign; the chart fills in.

The question the number raises is what three decades of evidence say it can and cannot tell. The defensible answer: higher hs-CRP is consistently associated with cardiovascular events, mortality, frailty, and dementia; two landmark trials showed the risk it flags is treatable; and the protein itself is probably not the cause of any of it.

Three decades of cohorts

The association is one of the most replicated in cardiovascular epidemiology. A 2000 study in the New England Journal of Medicine examined C-reactive protein and other inflammatory markers in predicting cardiovascular disease in women. A 2009 individual-participant meta-analysis in The Lancet pooled the data on CRP concentration and the risk of coronary heart disease, stroke, and mortality. A 2024 New England Journal of Medicine analysis followed inflammation, cholesterol, and lipoprotein(a) against 30-year cardiovascular outcomes in women. A 2025 record in Cardiovascular Diabetology carries the literature forward. Higher hs-CRP tracks with coronary disease, stroke, cardiovascular and non-vascular mortality — and, in the aging literature, with frailty and dementia. Consistently. Across cohorts. As association.

The trials that made it matter

What turned a marker into a target were two randomized trials. In JUPITER, published in the New England Journal of Medicine in 2008, people with elevated hs-CRP but normal LDL cholesterol were given rosuvastatin — and vascular events fell. In CANTOS, anti-inflammatory therapy aimed at the pathway upstream of CRP lowered recurrent events in patients selected by elevated hs-CRP. Together they established hs-CRP as a marker of residual inflammatory risk that can be treated — not merely observed.

What the number cannot tell you

The complications are fundamental. Mendelian randomization studies — nature's own randomized comparisons — indicate CRP itself is unlikely to be a causal factor in heart disease; the smoke is not the fire. Some analyses conclude the test adds only modest predictive value beyond traditional risk factors for most individuals. And CRP is profoundly non-specific: it rises with infection, obesity, smoking, and many other conditions, so a single elevated value cannot name its own source — the standard advice embedded in the evidence is to repeat the measurement once any acute illness has resolved.

For a reader, the practical meaning is a test best read as a weather report on inflammation rather than a diagnosis: useful for refining cardiovascular risk, meaningless in isolation, and always in need of a clinician's context and a repeat draw when you are well.

The tube, in the end, tells the laboratory how much smoke there is. Where the fire is — and whether putting it out changes the ending — the tube does not say.

Educational, not medical advice.